IL270097B2 - Cd 14 antagonist antibodies for treating neurodegenerative diseases - Google Patents

Cd 14 antagonist antibodies for treating neurodegenerative diseases

Info

Publication number
IL270097B2
IL270097B2 IL270097A IL27009719A IL270097B2 IL 270097 B2 IL270097 B2 IL 270097B2 IL 270097 A IL270097 A IL 270097A IL 27009719 A IL27009719 A IL 27009719A IL 270097 B2 IL270097 B2 IL 270097B2
Authority
IL
Israel
Prior art keywords
antibody
seq
sequence
antagonist antibody
cdr3
Prior art date
Application number
IL270097A
Other languages
English (en)
Hebrew (he)
Other versions
IL270097B1 (en
IL270097A (enExample
Inventor
Llewellyn REDLICH Garry
Original Assignee
Implicit Bioscience Ltd
Llewellyn REDLICH Garry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901462A external-priority patent/AU2017901462A0/en
Application filed by Implicit Bioscience Ltd, Llewellyn REDLICH Garry filed Critical Implicit Bioscience Ltd
Publication of IL270097A publication Critical patent/IL270097A/en
Publication of IL270097B1 publication Critical patent/IL270097B1/en
Publication of IL270097B2 publication Critical patent/IL270097B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL270097A 2017-04-21 2018-04-20 Cd 14 antagonist antibodies for treating neurodegenerative diseases IL270097B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017901462A AU2017901462A0 (en) 2017-04-21 Agents for treating or preventing motor neurone disease and uses therefor
AU2018900762A AU2018900762A0 (en) 2018-03-08 “agents for treating disease and uses therefor”
PCT/AU2018/050357 WO2018191786A1 (en) 2017-04-21 2018-04-20 Cd 14 antagonist antibodies for treating neurodegenerative diseases

Publications (3)

Publication Number Publication Date
IL270097A IL270097A (enExample) 2019-12-31
IL270097B1 IL270097B1 (en) 2024-01-01
IL270097B2 true IL270097B2 (en) 2024-05-01

Family

ID=63855469

Family Applications (2)

Application Number Title Priority Date Filing Date
IL309046A IL309046B2 (en) 2017-04-21 2018-04-20 CD14 antagonist antibodies for the treatment of neurodegenerative diseases
IL270097A IL270097B2 (en) 2017-04-21 2018-04-20 Cd 14 antagonist antibodies for treating neurodegenerative diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL309046A IL309046B2 (en) 2017-04-21 2018-04-20 CD14 antagonist antibodies for the treatment of neurodegenerative diseases

Country Status (8)

Country Link
US (2) US20200148780A1 (enExample)
EP (1) EP3612566A4 (enExample)
JP (2) JP2020517740A (enExample)
KR (1) KR20200015477A (enExample)
CN (1) CN110831975A (enExample)
AU (1) AU2018255489B2 (enExample)
IL (2) IL309046B2 (enExample)
WO (1) WO2018191786A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7371019B2 (ja) * 2018-05-10 2023-10-30 ザ・メソジスト・ホスピタル 疾病の予後と管理のための方法
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
CA3140023A1 (en) * 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
JP2022541646A (ja) * 2019-07-25 2022-09-26 インプリシット・バイオサイエンス・リミテッド 急性神経炎症傷害を処置するための方法および薬剤
AU2021219072B2 (en) * 2020-02-13 2024-10-03 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
CN113939533B (zh) * 2020-06-18 2022-12-06 武汉全景生物技术有限公司 抗可溶性cd14亚型抗体、试剂盒及其应用
EP4225796A4 (en) * 2020-10-07 2024-11-13 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用
CN120399098B (zh) * 2025-07-03 2025-09-16 上海玄言生物科技有限公司 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69032662T2 (de) * 1989-08-01 1999-03-11 Rockefeller University, New York, N.Y. Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
WO1996008272A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
JPWO2002042333A1 (ja) 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
KR101256837B1 (ko) * 2009-03-09 2013-04-22 경북대학교 산학협력단 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도
CN102869680B (zh) * 2010-02-26 2016-10-05 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
JP7371019B2 (ja) * 2018-05-10 2023-10-30 ザ・メソジスト・ホスピタル 疾病の予後と管理のための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AXTELLE T, PRIBBLE J., AXTELLE, 31 August 2001 (2001-08-31) *
FASSBENDER, K ET AL., FASSBENDER, 3 November 2003 (2003-11-03) *
ZHAO, WEIHUA ET AL., ZHAO, 26 July 2015 (2015-07-26) *

Also Published As

Publication number Publication date
CN110831975A (zh) 2020-02-21
WO2018191786A1 (en) 2018-10-25
IL309046A (en) 2024-02-01
IL270097B1 (en) 2024-01-01
JP2023090751A (ja) 2023-06-29
AU2018255489B2 (en) 2024-06-13
JP2020517740A (ja) 2020-06-18
US20220010025A1 (en) 2022-01-13
AU2018255489A1 (en) 2019-11-07
EP3612566A4 (en) 2021-03-03
US12297287B2 (en) 2025-05-13
IL270097A (enExample) 2019-12-31
IL309046B1 (en) 2024-11-01
US20200148780A1 (en) 2020-05-14
KR20200015477A (ko) 2020-02-12
IL309046B2 (en) 2025-03-01
EP3612566A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
US12297287B2 (en) CD14 antagonist antibodies for treating neurodegenerative diseases
KR20230005848A (ko) 항-trem2 항체의 사용 방법
US20240102094A1 (en) Trem2 agonist biomarkers and methods of use thereof
EP3082863B1 (en) Alpha-enolase specific antibodies and method of use in immune diseases
US20250230228A1 (en) Methods and agents for the treatment of ocular disease
WO2014100312A1 (en) Biomarkers for psoriasis treatment response
US10604566B2 (en) Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
US20220340687A1 (en) Methods of treatment using omalizumab
US20250186439A1 (en) Pyk2 inhibition modulates immune cell function
HK1168112A (en) Treatment for multiple sclerosis
WO2017183028A1 (en) Eotaxin-2 inhibitors in the treatment of fibromyalgia